TY - JOUR
T1 - Society for Maternal-Fetal Medicine Special Statement
T2 - Prophylactic low-dose aspirin for preeclampsia prevention—quality metric and opportunities for quality improvement
AU - Society for Maternal-Fetal Medicine (SMFM)
AU - SMFM Patient Safety and Quality Committee
AU - Combs, C. Andrew
AU - Kumar, Natasha R.
AU - Morgan, Jamie L.
N1 - Publisher Copyright:
© 2023
PY - 2023/8
Y1 - 2023/8
N2 - Prophylactic low-dose aspirin reduces the rates of preeclampsia, preterm birth, fetal growth restriction, and perinatal death in patients with risk factors for preeclampsia. Despite recommendations from the US Preventive Services Task Force, the American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine, low-dose aspirin use is reported in <50% of patients with high-risk factors and <25% of patients with >1 moderate-risk factor. These low use rates represent an important “quality gap” and demonstrate the need for quality improvement activities. In this article, we outline the specifications for a process metric to standardize the measurement of the rate of aspirin use. Furthermore, we outline an approach to conducting a quality improvement project to increase the use of aspirin by patients with risk factors for preeclampsia.
AB - Prophylactic low-dose aspirin reduces the rates of preeclampsia, preterm birth, fetal growth restriction, and perinatal death in patients with risk factors for preeclampsia. Despite recommendations from the US Preventive Services Task Force, the American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine, low-dose aspirin use is reported in <50% of patients with high-risk factors and <25% of patients with >1 moderate-risk factor. These low use rates represent an important “quality gap” and demonstrate the need for quality improvement activities. In this article, we outline the specifications for a process metric to standardize the measurement of the rate of aspirin use. Furthermore, we outline an approach to conducting a quality improvement project to increase the use of aspirin by patients with risk factors for preeclampsia.
KW - antiphospholipid syndrome
KW - diabetes mellitus (pregestational)
KW - fetal growth restriction
KW - hypertension
KW - kidney disease
KW - multifetal pregnancy
KW - preterm birth
KW - risk factors
KW - screening
KW - systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85163709154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163709154&partnerID=8YFLogxK
U2 - 10.1016/j.ajog.2023.04.039
DO - 10.1016/j.ajog.2023.04.039
M3 - Article
C2 - 37146704
AN - SCOPUS:85163709154
SN - 0002-9378
VL - 229
SP - B2-B9
JO - American journal of obstetrics and gynecology
JF - American journal of obstetrics and gynecology
IS - 2
ER -